Swiss equities offer attractive dividend yields amid market uncertainty By Investing.com

UBS sets a central SMI target of 14,000 by December 2026 (current 12,901), with an upside of 15,000 and downside of 10,500. The bank expects sustained positive earnings growth and highlights Swiss equities' roughly 3% dividend yield, favoring quality, dividend-growth and selected mid-cap/cyclical names while tactically reducing pharma exposure amid an AI-driven sector rotation. Key risks include the US‑Iran conflict and potential oil shocks weighing on energy costs, consumer sentiment and global growth, plus markedly negative currency effects expected into Q1 2026 before moderating.

Analysis

Energy-driven risk to margins is the most under-appreciated transmission mechanism to Swiss industrials: higher input-energy volatility forces accelerated capex on electrification and process automation, which benefits precision-engineering suppliers and industrial software vendors over the next 6-24 months while compressing near-term free cash flow for legacy OEMs. That dynamic creates a two-tier market where mid-cap suppliers can expand margins as OEMs de-risk supply chains, producing idiosyncratic earnings upside that broad SMI multiples won’t immediately reflect.

The AI rotation has created momentum-driven dislocations across defensive healthcare franchises; algorithmic flows have likely overstated permanence of earnings re‑rating and, in several cases, pushed implied volatility and options skew to levels that make buying insurance cheap. Over a 3–12 month horizon, selective mean-reversion is plausible as adoption timelines clarify and investors refocus on cash return durability rather than headline AI linkage.

Currency mechanics are a hidden lever: renewed CHF resilience would amplify the pain for exporters’ reported USD/ EUR revenues, while a softer CHF would mechanically boost dividend yield attractiveness for foreign holders — this creates a convex payoff where macro headlines (energy/geopolitics) drive outsized P/L for currency-hedged dividend trades within quarters. Monetary-policy signaling from the SNB remains the key catalyst to compress or expand that convexity in the next 1–3 months.

Investor positioning looks skewed toward safety-yielding names; the second-order effect is reduced liquidity in cyclical mid-caps, widening bid-ask and creating execution opportunities for patient, sizeable buys. Tail risk remains a protracted energy shock or a rapid escalation in geopolitical conflict that would reprice risk premia across both credit and equities within days, reversing tactical winners into losers rapidly.

Key Decisions for Investors

• Long UBS (UBS) stock, size 2–3% NAV, horizon 9–18 months: overweight bank exposure to Swiss wealth flows and fee resilience; hedge 30–50% of FX exposure via short EUR/CHF forwards. Target +25% upside vs 15% downside (stop-loss -12%); reduce on SNB hawkish surprise.
• Buy Swiss dividend ETF (EWL) hedged to USD, horizon 6–12 months: allocate 1–2% NAV to capture convexity if CHF softens and dividend yield re-rating resumes. Use a 6–9 month covered-call overlay to enhance yield; accept capped upside for current yield pickup.
• Short selected oversized pharma defensives (e.g., RHHBY/NVS) via 3–6 month put spreads sized 0.5–1% NAV: play mean-reversion from AI-driven over-rotation and elevated options skew. Risk: regulatory/positive M&A news; cap loss at premium paid (~limited downside).
• Long narrow industrial/supplier mid-caps via focused ETF or basket (size 2% NAV), horizon 12–24 months: target companies supplying electrification/automation where higher energy costs accelerate order books. Trim into 20–30% rallies; watch order cadence as leading indicator.
• Tail hedge: buy 6–12 month Brent call spread (e.g., USO call spread) sized 0.5% NAV to protect against a sharp oil-shock re‑pricing of global risk premia. P&L: small cost for large drawdown protection; unwind if Brent stays rangebound for 3 consecutive months.